Aspire-Lakewood Holdings Inc(ASBP) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -106.59 | Insider Own | 20.1% | Shs Outstand | 1.3M | Perf Week | -15.22% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 1.1M | Perf Month | -19.89% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | - | Inst Own | 8.11% | Short Float | 0.53% | Perf Quarter | -8.71% |
| Income | -0.01B | P/S | 100.01 | EPS this Y | - | Inst Trans | 42.05% | Short Ratio | 0.2 | Perf Half Y | 31.79% |
| Sales | 0.00B | P/B | 0.79 | EPS next 5Y | - | ROA | -152.09% | Short Interest | 0.01M | Perf YTD | -95.5% |
| Book/sh | 9.08 | P/C | 0.82 | EPS past 3/5Y | - | ROE | -1032.14% | 52W High | -96.53% ($205.20) | Perf Year | -93.92% |
| Cash/sh | 8.68 | P/FCF | - | Sales past 3/5Y | - | ROIC | -93.97% | 52W Low | 115.47% ($3.31) | Perf 3Y | -99.95% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 94.71% | Gross Margin | 18.35% | Volatility(W/M) | 10.22% 8.42% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | -21.69 | Sales Y/Y TTM | - | Oper. Margin | -7259.85% | ATR (14) | 0.68 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 7.81 | EPS Q/Q | 97.46% | Profit Margin | -11314.12% | RSI (14) | 39.01 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 7.99 | Sales Q/Q | - | SMA20 | -11.13% ($8.02) | Beta | 0.16 | Target Price | - |
| Payout | - | Debt/Eq | 0 | Earnings | - | SMA50 | -14.31% ($8.32) | Rel Volume | 0.82 | Prev Close | $7.65 |
| Employees | - | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -48.31% ($13.79) | Avg Volume(3M) | 0.03M | Price | $7.13 |
| IPO | 2022/4/11 | Option/Short | No/Yes | Trades | 256 | Volume | 24,160 | Change | -6.8% |
An early-stage biopharmaceutical company focused on developing novel drug delivery technologies, utilizing sublingual delivery (under the tongue) to develop a range of products including heart medications, pain relievers, and hormone therapies. The company is pursuing early monetization through its Buzz Bomb caffeine product.
Over the past 1 year, on the lower side
97% below its 1-year high.
Traded about as much as usual. That is 82% of its average volume.
ASBP has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $10,001. Peers typically go for $29.
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -100.0%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 8.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #51 of 55 in the industry
Based on market cap of $10M.
FAQ
ASBP belongs to the Consumer Cyclical sector and operates in the Auto Parts industry.
The market cap of ASBP is approximately $10M, ranking 5,345 within its sector.
ASBP has recorded a 52-week high of $205.20 and a low of $3.31.